MAZE
Maze Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.70
+7.88%Oct 16, 2026, 20:14 UTC
Maze Therapeutics exchanged 2,776,007 shares of common stock for pre-funded warrants to purchase the same number of shares at an exercise price of $0.001 per share, under an agreement with four Frazier Life Sciences funds.
Oct 6, 2026, 20:05 UTC
Maze Therapeutics, Inc. announced that it will present data on its MZE829 and MZE782 programs at ASN Kidney Week 2026 in Denver, October 21–25.
Source:Aug 17, 2026, 00:00 UTC
Maze Therapeutics, Inc. appointed Paula A. Johnson and Sophie Kornowski as Class III and Class I directors, respectively, effective August 13, 2026, each receiving an option to purchase 36,000 shares of the company's common stock.